News Releases

Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2023 financial results on...

Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024...

Moleculera Labs, Inc, a precision medicine company pioneering immune-mediated neuropsychiatric testing, today announced a strategic collaboration with Quest Diagnostics (DGX: NYSE), the nation’s...

Goal to combine Ultima’s highly sensitive, low-cost technology with Quest’s oncology expertise and national scale in order to improve patient access, affordability and outcomes FREMONT, Calif...

Transaction to broaden access to innovative, quality diagnostic information services for providers and patients SECAUCUS, N.J., Jan. 8, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the...

Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology's personalized MRD...

Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that Jim Davis, Chairman, CEO and President, and Sam Samad, Executive Vice...

Seasoned healthcare executive and oncologist joins Executive Leadership Team SECAUCUS, N.J., Dec. 20, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of...

Xylazine found in 1 in 12 specimens tested, finds new 'Drug Misuse in America' Health Trends® report on the rising polysubstance crisis SECAUCUS, N.J., Dec. 19, 2023 /PRNewswire/ -- Quest...

Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Rutgers Cancer Institute of New Jersey to use Haystack Oncology's industry-leading personalized...

Quest will provide research consulting, laboratory testing and data analytics services to generate diagnostics insights supporting population health strategy for hepatitis C SECAUCUS, N.J., Dec....

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that for the seventh straight year it has received a score of 100% on the Human...

Relationship leverages Quest's sequencing and specimen collection expertise with Scipher's precision medicine technology SECAUCUS, N.J. and WALTHAM, Mass., Nov. 28, 2023 /PRNewswire/ -- Quest...

UDX also announces the initial closing of its series B financing of approximately $70 million with investors, including Quest Diagnostics Financing to support UDX's pursuit of FDA premarket...

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.71 per share,...

Quest Mobile™ has 5,000 trained mobile phlebotomists whose reach will extend to 44 states by the end of 2023 SECAUCUS, N.J., Nov. 9, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the...

Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the pricing of a public offering of $750 million aggregate principal...

Diadem SpA, (Diadem), a company developing one of the first blood-based tests for the early and accurate prediction of clinical progression to Alzheimer's disease (AD), today announced that it has...

Third quarter revenues of $2.30 billion, down 7.7% from 2022 Third quarter reported diluted earnings per share ("EPS") of $1.96, down 9.7% from 2022; and adjusted diluted EPS of $2.22, down 5.9%...

Neway, LLC, the U.S. leader in value-based dialysis lab care, today announced a strategic lab services arrangement with Quest Diagnostics (NYSE: DGX) that aims to accelerate dialysis laboratory...

Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 2023 financial results on Tuesday, October...

Stamford, Conn. – Sept. 13, 2023 – Americares and Quest Diagnostics, with the Quest Diagnostics Foundation, are teaming up to provide no-cost diagnostic services and expanded telehealth...

Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will...

Quest Diagnostics (NYSE: DGX), the leader in diagnostic information services, today released its 2022 Corporate Responsibility Report. The report provides information on the company's strategy...

Rutgers and Quest Diagnostics are expanding their collaboration to further improve access to critical primary care services for uninsured patients of the university’s Health Outreach Practice...

Quest and Sarepta Therapeutics Expand Collaboration to Develop AAV Companion Diagnostics (CDx) for Sarepta's Gene Therapies SECAUCUS, N.J. and CAMBRIDGE, Mass., Aug. 30, 2023 /PRNewswire/ -- Quest...

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.71 per share,...

Ten-fold increase in death risk in individuals with high levels of myeloperoxidase, or MPO, compared to those with low levels, according to analysis of 3,700 patients of MDVIP tested by Quest...

AD-Detect™ Test for Alzheimer's Disease is the first blood-based biomarker test for assessing beta amyloid protein, a recognized marker of Alzheimer's disease, available for consumer purchase to...

Second quarter revenues of $2.34 billion, down 4.7% from 2022 Second quarter reported diluted earnings per share ("EPS") of $2.05, up 4.6% from 2022; and adjusted diluted EPS of $2.30, down 2.5%...

Lab service utilizes Envision Science's proprietary biomarkers and technology with a goal of improving diagnosis and grading of prostate cancer SECAUCUS, N.J. and MELBOURNE, Australia, July 13, 2023 /

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced it has been named to the 2023 Disability Equality Index® (DEI) Best Places to Work for...

First consumer genetic health test under the Quest brand provides insights based on DNA, with unique features that include next-generation sequencing, robust support services, physician ordering,...

Organized by nine laboratories on five continents, the study by some members of the Global Diagnostics Network, a Quest Diagnostics-led strategic working group, is the largest to evaluate...

First and only FDA-cleared PdG (progesterone metabolite) home test to help confirm successful ovulation SECAUCUS, N.J., July 6, 2023 /PRNewswire/ -- Women seeking to start or expand a family can...

June 2023 For more information or to schedule an interview with one of our medical experts, please email mediacontact@questdiagnostics.com. Breaking Science News: Only one in three adults (34%)...

Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter 2023 financial results on Wednesday, July...

Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, today announced that it has completed its previously announced acquisition of Haystack Oncology....

Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Jefferies Global Healthcare Conference....

Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the William Blair 43rd Annual Growth Stock...

Increase Seen in the General U.S. Workforce Started Same Year First States Legalized Recreational Marijuana Overall Workforce Drug Test Positivity Persisted at Two-Decade High Across All Workers...

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Luis A. Diaz, Jr., M.D. to serve as a...

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.71 per share,...

Beginning February 2023, Quest Diagnostics plans to discontinue providing a monthly COVID-19 media statement, including monthly COVID-19 volume and turnaround time figures. Instead, this media...

The collaboration aims to help physicians improve detection and care of potentially treatable causes of cognitive decline SECAUCUS, N.J. and RALEIGH, N.C., May 4, 2023 /PRNewswire/ -- Quest...

First quarter revenues of $2.33 billion, down 10.7% from 2022 First quarter reported diluted earnings per share ("EPS") of $1.78, down 39.0% from 2022; and adjusted diluted EPS of $2.04, down...

Goal to improve patient outcomes through early, accurate detection of residual or recurring cancer Haystack's highly sensitive minimal-residual disease cancer-detection technology to be combined...

Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, and NewYork-Presbyterian, one of the nation's largest and most comprehensive academic medical...

Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2023 financial results on Thursday, April...

Resources focus on children’s wider circle of care by supporting parents and caregivers in communicating with providers, through videos, interactive role-playing, digital storybooks, printable...